VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 76 filers reported holding VAXCYTE INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $51,344,405 | +2.1% | 1,007,148 | 0.0% | 1.09% | +19.8% |
| Q2 2023 | $50,296,971 | +84.0% | 1,007,148 | +38.1% | 0.91% | +69.6% |
| Q1 2023 | $27,339,374 | -55.6% | 729,439 | -43.2% | 0.54% | -54.4% |
| Q4 2022 | $61,525,892 | +164.9% | 1,283,126 | +32.6% | 1.18% | +173.1% |
| Q3 2022 | $23,230,000 | -29.5% | 967,900 | -36.1% | 0.43% | -27.8% |
| Q2 2022 | $32,937,000 | -9.9% | 1,513,659 | 0.0% | 0.60% | +0.7% |
| Q1 2022 | $36,555,000 | +40.1% | 1,513,659 | +38.0% | 0.59% | +77.0% |
| Q4 2021 | $26,090,000 | -0.6% | 1,096,700 | +6.0% | 0.34% | +16.3% |
| Q3 2021 | $26,249,000 | +23.3% | 1,034,665 | +9.4% | 0.29% | +34.0% |
| Q2 2021 | $21,281,000 | +66.1% | 945,400 | +45.7% | 0.22% | +79.2% |
| Q1 2021 | $12,813,000 | -23.5% | 648,774 | +2.9% | 0.12% | -18.4% |
| Q4 2020 | $16,746,000 | -47.1% | 630,260 | -1.6% | 0.15% | -63.1% |
| Q3 2020 | $31,641,000 | +17.8% | 640,760 | -24.6% | 0.40% | +5.3% |
| Q2 2020 | $26,869,000 | – | 850,000 | – | 0.38% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 4,168,718 | $82,124,000 | 28.36% |
| Medicxi Ventures Management (Jersey) Ltd | 1,887,478 | $37,277,000 | 21.71% |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,405,421 | $27,757,000 | 8.90% |
| FRAZIER MANAGEMENT LLC | 2,309,554 | $45,614,000 | 3.66% |
| RA Capital Management | 3,865,808 | $76,350,000 | 1.15% |
| TPG Group Holdings (SBS) Advisors, Inc. | 4,558,475 | $90,030,000 | 1.05% |
| Soleus Capital Management, L.P. | 293,650 | $5,800,000 | 1.04% |
| Opaleye Management Inc. | 357,800 | $7,067,000 | 1.04% |
| SABBY MANAGEMENT, LLC | 178,992 | $3,535,000 | 0.69% |
| Penn Mutual Asset Management, LLC | 22,227 | $439,000 | 0.50% |